Recent studies have shown that antegrade access for treatment of infrainguinal peripheral vascular disease is associated with decreased radiation exposure and contrast use without a significant increase in access complication, although data are limited on antegrade superficial femoral artery (SFA) access for larger sheath sizes. We aim to describe a single institution's contemporary experience with percutaneous antegrade SFA access.
A retrospective review of percutaneous, infrainguinal endovascular interventions for arterial occlusive disease at a major academic institution was conducted between 2018 and 2020. Antegrade, percutaneous, SFA access cases were included. Information on demographics, indication, sheath size, arteries treated, type of intervention, concurrent pedal access, closure devices, and complications was collected and analyzed.
A total of 45 patients with an average body mass index of 25.25 were identified. Indications for intervention included tissue loss (64.4%), rest pain (6.7%), claudication (13.3%), and acute limb ischemia (11.1%). Of which, 80.0% of patients had multilevel interventions. Angioplasty was performed in 68.8% of patients, stenting in 8.3%, atherectomy in 15.6%, and thrombectomy in 7.3%. Nearly a quarter of cases involved concurrent pedal access. Maximum sheath size was 4F for 4.4% of patients, 5F for 28.9%, 6F for 46.7%, 7F for 11.1%, and 8F for 8.9%. The closure device was utilized in 75.6% of cases, with no closure device failures. In the entire cohort, there were no demonstrated access site complications.
This study demonstrates percutaneous, antegrade SFA access for complex endovascular interventions for infrainguinal occlusive disease can be effectively utilized, even with larger sheath size. Moreover, routine use of closure devices is safe, improving patient comfort and expediting time to ambulation.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Annals of Vascular Surgery
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomized controlled trial.Lancet. 2005; 366: 1925-1934
- Retrograde approach for complex popliteal and tibioperoneal occlusions.J Endovasc Ther. 2008; 15: 594-604
- Superficial femoral artery access for lower extremity arterial disease is safe and effective in the outpatient setting.Ann Vasc Surg. 2021; 72: 175-181
- Vascular Quality Initiative. Common femoral artery antegrade and retrograde approaches have similar access site complications.J Vasc Surg. 2019; 69: 1160-1166.e2
- Vascular closure device. Terumo.(Available at:)https://www.terumois.com/content/dam/terumopublic/products/ANGIO-SEAL/Terumo%20Angio-Seal%20VIP%20IFU.pdfDate accessed: October 23, 2019
- Complication rates associated with antegrade use of vascular closure devices: a systematic review and pooled analysis.J Vasc Surg. 2021; 73: 722-730.e1
- Risk factors for puncture site complications after endovascular procedures in patients with peripheral arterial disease.Vasc Endovascular Surg. 2015; 49: 160-165
- Mastering the antegrade femoral artery access in patients with symptomatic lower limb ischemia: learning curve, complications, and tech- nical tips and tricks.Catheter Cardiovasc Interv. 2006; 68: 835-842
- Complication rates for percutaneous lower extremity arterial antegrade access.Arch Surg. 2011; 146: 432-435
- Safety and outcomes of ipsilateral antegrade angioplasty for femoropopliteal disease.J Vasc Surg. 2018; 52: 93-97
Published online: December 05, 2022
Accepted: November 2, 2022
Received: July 7, 2022
© 2022 Elsevier Inc. All rights reserved.